Literature DB >> 22231618

The landscape after LUNAR: rituximab's crater-filled path.

Liz Lightstone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22231618     DOI： 10.1002/art.34362

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  13 in total

Review 1.  Rationale for B cell targeting in SLE.

Authors:  Iñaki Sanz
Journal:  Semin Immunopathol       Date:  2014-04-25       Impact factor: 9.623

2.  Systemic lupus erythematosus: Extent and patterns of off-label use of rituximab for SLE.

Authors:  Iñaki Sanz
Journal:  Nat Rev Rheumatol       Date:  2016-11-22       Impact factor: 20.543

Review 3.  The contribution of the programmed cell death machinery in innate immune cells to lupus nephritis.

Authors:  FuNien Tsai; Harris Perlman; Carla M Cuda
Journal:  Clin Immunol       Date:  2016-10-22       Impact factor: 3.969

4.  Available evidence and outcome of off-label use of rituximab in clinical practice.

Authors:  I Danés; A Agustí; A Vallano; J Martínez; C Alerany; A Ferrer; A López; J Cortés-Hernández; J A Bosch
Journal:  Eur J Clin Pharmacol       Date:  2013-05-23       Impact factor: 2.953

Review 5.  Biologics for the treatment of autoimmune renal diseases.

Authors:  Stephen R Holdsworth; Poh-Yi Gan; A Richard Kitching
Journal:  Nat Rev Nephrol       Date:  2016-03-07       Impact factor: 28.314

Review 6.  The treatment of systemic lupus proliferative nephritis.

Authors:  Marilynn G Punaro
Journal:  Pediatr Nephrol       Date:  2012-11-22       Impact factor: 3.714

7.  Biologics for childhood systemic vasculitis.

Authors:  Keiji Akamine; Marilynn Punaro
Journal:  Pediatr Nephrol       Date:  2018-09-10       Impact factor: 3.714

Review 8.  Novel therapeutic agents in clinical development for systemic lupus erythematosus.

Authors:  Natasha Jordan; Pamela M K Lutalo; David P D'Cruz
Journal:  BMC Med       Date:  2013-05-03       Impact factor: 8.775

Review 9.  Targeting the B-cell pathway in lupus nephritis: current evidence and future perspectives.

Authors:  Panagiotis Pateinakis; Athina Pyrpasopoulou
Journal:  ScientificWorldJournal       Date:  2013-09-26

10.  CD20 antibody primes B lymphocytes for type I interferon production.

Authors:  Dongsheng Xu; Andrew Staedman; Luwen Zhang
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.